S. Salvador

Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.

Allan G. Rempel, D. Huntsman, Dianne Miller, 2008, Gynecologic oncology.

The Impact of Intra-Uterine Manipulators on Outcome and Recurrence Patterns of Endometrial Cancer Patients Undergoing Minimally Invasive Surgery

K. Jardon, S. Lau, N. Michaan, 2021 .

The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas

D. Huntsman, M. Köbel, Dianne Miller, 2009, International Journal of Gynecologic Cancer.

Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.

A. Whittemore, L. Kiemeney, M. Pike, 2013, International journal of epidemiology.

The role of the fallopian tube in ovarian cancer.

A. Tinker, D. Huntsman, K. Swenerton, 2012, Clinical advances in hematology & oncology : H&O.

Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death.

A. Talhouk, S. Leung, D. Huntsman, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification

A. Talhouk, S. Leung, A. Tinker, 2022, Modern Pathology.

Ovarian stimulation for fertility preservation in a woman with borderline serous ovarian tumor causing a large fluctuating subcutaneous fluid collection: a case report

R. Hizkiyahu, M. Dahan, S. Salvador, 2021, Clinical and Experimental Obstetrics & Gynecology.

OP015/#492 Further stratification of no specific molecular profile (NSMP/P53WT) endometrial carcinomas to refine prognosis and identify therapeutic opportunities

A. Talhouk, M. Köbel, C. Gilks, 2021, Oral Featured Posters.

Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific Populations

C. Bouchard, J. Bentley, Nicole Todd, 2023, Current oncology.

537P A phase I/II study of oral chk1 inhibitor LY2880070 in combination with low-dose gemcitabine in patients with advanced or metastatic ovarian cancer

A. Oza, D. Provencher, A. Shields, 2022, Annals of Oncology.